Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV

Gene Therapy

Volumn 16, Issue 5, 2009, Pages 645-659

  Singh, S R ^a   Grossniklaus, H E ^b   Kang, S J ^b   Edelhauser, H F ^b   Ambati, B K ^c   Kompella, U B ^a,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b EMORY EYE CENTER   (United States)

^c John Moran Eye Centre   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; POLYGLACTIN; TRANSFERRIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE TARGETING; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHOTORECEPTOR; PHYSICAL CHEMISTRY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHEMISTRY, PHYSICAL; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; INJECTIONS, INTRAVENOUS; LASERS; MALE; MICROSCOPY, CONFOCAL; NANOPARTICLES; OLIGOPEPTIDES; RATS; RATS, INBRED BN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINA; RETINAL PIGMENT EPITHELIUM; TISSUE DISTRIBUTION; TRANSFERRIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 67349119829     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.185     Document Type: Article

References (61)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-293.
2. Zarbin M, Szirth B. Current treatment of age-related macular degeneration. Optom Vis Sci 2007; 84: 559-572.
3. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40: 352-368.
4. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2030-2036.
5. Singh N, Amin S, Richter E, Rashid S, Scoglietti V, Jani PD et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 2005; 46: 1647-1652.
6. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 81: 20-31.
7. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
8. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004; 103: 3883-3889.
9. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995; 270: 28316-28324.
10. Lai CC, Wu WC, Chen SL, Xiao X, Tsai TC, Huan SJ et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001; 42: 2401-2407.
11. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43: 1994-2000.
12. Shyong MP, Lee FL, Kuo PC, Wu AC, Cheng HC, Chen SL et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis 2007; 13: 133-141.
13. Provost N, Le Meur G, Weber M, Mendes-Madeira A, Podevin G, Cherel Y et al. Biodistribution of rAAV vectors following intraocular administration: Evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther 2005; 11: 275-283.
14. Peeters L, Sanders NN, Braeckmans K, Boussery K, Van de Voorde J, De Smedt SC et al. Vitreous: A barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci 2005; 46: 3553-3561.
15. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res 2003; 20: 576-583.
16. Pitkanen L, Pelkonen J, Ruponen M, Rönkkö S, Urtti A. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J 2004; 6: E25.
17. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R et al Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44: 3562-3569.
18. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 2007; 13: 746-757.
19. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Therapy 2005; 12: 1544-1550.
20. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006; 1: E38.
21. Kawakami S, Harada A, Sakanaka K, Nishida K, Nakamura J, Sakaeda T et al. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int J Pharm 2004; 278: 255-262.
22. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis 2006; 12: 1185-1198.
23. Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006; 66: 11878-11887.
24. Zhu C, Zhang Y, Pardridge WM. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci 2002; 43: 3075-3080.
25. Zhu C, Zhang Y, Zhang YF, Yi Li J, Boado RJ, Pardridge WM. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med 2004; 6: 906-912.
26. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715.
27. Marcinkiewicz C, Rosenthal LA, Marcinkiewicz MM, Kowalska MA, Niewiarowski S. One-step affinity purification of recombinant alphavbeta3 integrin from transfected cells. Protein Expr Purif 1996; 8: 68-74.
28. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93 9764-9769.
29. He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 2007; 26: 649-673.
30. Chowers I, Wong R, Dentchev T, Farkas RH, Iacovelli J, Gunatilaka TL et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2006; 47: 2135-2140.
31. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC et al Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005; 11: 124-132.
32. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007; 120: 18-26.
33. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001; 75: 211-224.
34. Zweers ML, Engbers GH, Grijpma DW, Feijen J. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide). J Control Release 2004; 100: 347-356.
35. Yang R, Yang SG, Shim WS, Cui F, Cheng G, Kim IW et al. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 2008 (e-pub ahead of print).
36. Frangos SG, Knox R, Yano Y, Chen E, Di Luozzo G, Chen AH et al. The integrin-mediated cyclic strain-induced signaling pathway in vascular endothelial cells. Endothelium 2001; 8: 1-10.
37. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol 2003; 55: 1199-1206.
38. Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Therapy 2000; 7: 1896-1905.
39. Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 2001; 42: 2664-2672.
40. Yasukawa T, Kimura H, Tabata Y, Kamizuru H, Miyamoto H, Honda Y et al Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination. Invest Ophthalmol Vis Sci 2002; 43: 842-848.
41. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y et al Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci 1999; 40: 2690-2696.
42. Anzai K, Yoneya S, Gehlbach PL, Imai D, Wei LL, Mori K. Laser photocoagulation and, to a lesser extent, photodynamic therapy target and enhance adenovirus vector-mediated gene transfer in the rat retina. Invest Ophthalmol Vis Sci 2005; 46: 3883-3891.
43. Suzuma K, Takagi H, Otani A, Honda Y. Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 1998; 39: 1028-1035.
44. Yi X, Ogata N, Komada M, Yamamoto C, Takahashi K, Omori K et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 1997; 235: 313-319.
45. Yefimova MG, Jeanny JC, Guillonneau X, Keller N, Nguyen-Legros J, Sergeant C et al. Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest Ophthalmol Vis Sci 2000; 41: 2343-2351.
46. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007; 28: 869-876.
47. Furumoto K, Ogawara K, Yoshida M, Takakura Y, Hashida M, Higaki K et al. Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. Biochim Biophys Acta 2001; 1526: 221-226.
48. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 2007; 49: 217-229.
49. Ogawara K, Yoshida M, Furumoto K, Takakura Y, Hashida M, Higaki K et al. Uptake by hepatocytes and biliary excretion of intravenously administered polystyrene microspheres in rats. J Drug Target 1999; 7: 213-221.
50. Anderson DH, Johnson LV, Hageman GS. Vitronectin receptor expression and distribution at the photoreceptor-retinal pigment epithelial interface. J Comp Neurol 1995; 360: 1-16.
51. Hunt RC, Dewey A, Davis AA. Transferrin receptors on the surfaces of retinal pigment epithelial cells are associated with the cytoskeleton. J Cell Sci 1989; 92 (Part 4): 655-666.
52. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007; 10 103-117.
53. Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 1998; 82: 1063-1071.
54. Andrieu-Soler C, Bejjani RA, de Bizemont T, Normand N, BenEzra D, Behar-Cohen F. Ocular gene therapy: A review of nonviral strategies. Mol Vis 2006; 12: 1334-1347.
55. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421-428.
56. Lu K, Zhou Y, Kaufman K, Mott R, Ma JX. Rat strain-dependent susceptibility to ischemia-induced retinopathy associated with retinal vascular endothelial growth factor regulation. J Mol Endocrinol 2007; 38: 423-432.
57. Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 2006; 215: 100-108.
58. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci 2006; 47: 1149-1160.
59. Zacks DN, Ezra E, Terada Y, Michaud N, Connolly E, Gragoudas ES et al Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: Angiographic and histologic characterization. Invest Ophthalmol Vis Sci 2002; 43: 2384-2391.
60. Campos M, Amaral J, Becerra SP, Farris RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47: 5163-5170.
61. Glushakova LG, Timmers AM, Pang J, Teusner JT, Hauswirth WW. Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors. Invest Ophthalmol Vis Sci 2006; 47 3505-3513.